Inozyme Pharma, Inc.

NasdaqGS INZY

Inozyme Pharma, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.03

Inozyme Pharma, Inc. Revenue Per Share is USD 0.03 for the Trailing 12 Months (TTM) ending September 30, 2024. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Inozyme Pharma, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
  • Inozyme Pharma, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00, a 0.00% change year over year.
  • Inozyme Pharma, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
NasdaqGS: INZY

Inozyme Pharma, Inc.

CEO Dr. Douglas A. Treco Ph.D.
IPO Date July 24, 2020
Location United States
Headquarters 321 Summer Street
Employees 59
Sector Health Care
Industries
Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Similar companies

HOOK

HOOKIPA Pharma Inc.

USD 1.86

4.49%

MREO

Mereo BioPharma Group plc

USD 3.06

-8.38%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

ELDN

Eledon Pharmaceuticals, Inc.

USD 3.71

-4.63%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.56

-1.89%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.13

-1.57%

PDSB

PDS Biotechnology Corporation

USD 1.39

-2.11%

StockViz Staff

January 15, 2025

Any question? Send us an email